Argenica Therapeutics Ltd
ASX:AGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Argenica Therapeutics Ltd
Selling, General & Administrative
Argenica Therapeutics Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Argenica Therapeutics Ltd
ASX:AGN
|
Selling, General & Administrative
-AU$2.6m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-163%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Selling, General & Administrative
-AU$20.5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Selling, General & Administrative
-AU$192.1m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Selling, General & Administrative
-AU$6.2m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-7%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Selling, General & Administrative
-AU$11.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Selling, General & Administrative
-AU$41.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-7%
|
|
Argenica Therapeutics Ltd
Glance View
Argenica Therapeutics Ltd. provides neuroprotective treatment. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2021-06-11. Argenica’s lead candidate, ARG-007, aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury. Argenica has accumulated a comprehensive body of published pre-clinical studies demonstrating efficacy of ARG-007 in multiple models of stroke and other central nervous system injury models, including stroke, traumatic brain injury and perinatal hypoxia ischaemia.
See Also
What is Argenica Therapeutics Ltd's Selling, General & Administrative?
Selling, General & Administrative
-2.6m
AUD
Based on the financial report for Jun 30, 2025, Argenica Therapeutics Ltd's Selling, General & Administrative amounts to -2.6m AUD.
What is Argenica Therapeutics Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-163%
Over the last year, the Selling, General & Administrative growth was -15%. The average annual Selling, General & Administrative growth rates for Argenica Therapeutics Ltd have been -13% over the past three years , -163% over the past five years .
